Replacing TDF With TAF for HIV Tied to Adverse Metabolic Changes
FRIDAY, April 9, 2021 -- For people with HIV receiving tenofovir-based antiretroviral therapy (ART), replacing tenofovir disoproxil fumarate (TDF) with tenofovir alafenamide (TAF) is associated with adverse metabolic changes, including weight increase and development of obesity, according to a study published online March 16 in the Annals of Internal Medicine.
Bernard Surial, M.D., from the University of Bern in Switzerland, and colleagues examined weight changes, development of overweight/obesity, and changes in lipid levels 18 months after replacing TDF with TAF in a cohort study involving 4,375 adults living with HIV with follow-up between Jan. 1, 2016, and July 31, 2019. Of the participants, 79.6 percent switched to TAF and 20.4 percent continued with TDF.
The researchers found that switching to TAF was associated with an adjusted mean weight increase of 1.7 kg after 18 months compared with 0.7 kg with continued use of TDF. Among individuals with a normal body mass index, 13.8 and 8.4 percent of those who switched to TAF and continued TDF, respectively, became overweight/obese. Increases in adjusted mean total cholesterol (0.25 mmol/L), high-density lipoprotein cholesterol (0.05 mmol/L), low-density lipoprotein cholesterol (0.12 mmol/L), and triglyceride (0.18 mmol/L) levels were seen after 18 months in association with switching to TAF.
"The decision to prefer TAF over TDF as a component of ART should be individualized and accompanied by the repeated assessment of cardiometabolic risk factors, including weight and lipids," the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
© 2021 HealthDay. All rights reserved.
Posted: April 2021
Read this next
FRIDAY, April 30, 2021 -- Life expectancy among people with HIV receiving antiretroviral therapy (ART) has significantly improved in Latin America and the Caribbean, according to...
FRIDAY, April 23, 2021 -- People living with HIV (PLWH) without known cardiovascular disease have an increased prevalence and volume of noncalcified coronary plaque, as measured...
MONDAY, April 19, 2021 -- Forty-two percent of transgender women with a valid HIV test result have a positive result, with considerable regional and ethnic/racial variation,...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.